Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins by unknown
Disialogangliosides GD2 and GD3 Are Involved in the Attachment 
of Human Melanoma and Neuroblastoma Cells 
to Extracellular Matrix Proteins 
David A. Cheresh,* Michael D. Pierschbacher,  * Michael A. Herzig,* and Kalpana Mujoo* 
•  Department of Immunology, Scripps Clinic and Research Foundation, and *The Cancer Research Center, La Jolla Cancer 
Research Foundation,  La Jolla, California 92037. Address correspondence to Dr. Cheresh. 
Abstract. Human melanoma cells express relatively 
large amounts of the disialogangliosides GD3 and 
GD2 on their surface whereas neuroblastoma cells ex- 
press GD2 as a major ganglioside. 1 Monoclonal anti- 
bodies (Mabs) directed specifically to the carbohydrate 
moiety of GD3 and GD2 inhibit melanoma and neu- 
roblastoma cell attachment to various substrate adhe- 
sive proteins, e.g. collagen, vitronectin, laminin, fibro- 
nectin, and a heptapeptide, glycyl-L-arginyl-glycyl-L- 
aspartyl-L-seryl-L-prolyl-L-cysteine,  which constitutes 
the cell attachment site of fibronectin. Cells that are 
preattached to a fibronectin substrate can also be in- 
duced to detach and round up in the presence of 
purified anti-ganglioside Mab. Moreover, when mela- 
noma cells that contain both GD2 and GD3 are incu- 
bated with Mabs directed to both of these molecules 
an additive inhibition is observed. The specificity of 
this inhibition is demonstrated since Mabs of various 
isotypes directed to either protein or carbohydrate epi- 
topes on a number of other major melanoma or neu- 
roblastoma cell surface antigens have no effect on cell 
attachment. A study of the kinetics involved in this 
inhibition indicates that signifcant effects occur dur- 
ing the first 5 min of cell attachment, suggesting an 
important role for GD2 and GD3 in the initial events 
of cell-substrate interactions. The role of gangliosides 
in cell attachment apparently does not directly involve 
a strong interaction with fibronectin since we could 
not observe any binding of radiolabeled fibronectin or 
fragments of the molecule known to contain the cell 
attachment site to melanoma gangliosides separated 
on thin-layer chromatograms. An alternative explana- 
tion would be that gangliosides may play a role in the 
electrostatic requirements for cell-substrate interac- 
tions. In this regard, controlled periodate oxidation of 
terminal, unsubstituted sialic acid residues on the cell 
surface not only specifically destroys the antigenic epi- 
topes on GD2 and GD3 recognized by specific Mabs 
but also inhibits melanoma cell and neuroblastoma 
cell attachment. In fact, the periodate-induced gan- 
glioside oxidation and the inhibition of cell attach- 
ment are equally dose dependent. These data suggest 
that cell-substratum interactions may depend in part 
on the electrostatic environment provided by terminal 
sialic acid residues of cell surface gangliosides and pos- 
sibly other anionic glycoconjugates. 
S 
IALIC  acid-bearing  glycolipids,  i.e.,  gangliosides,  ex- 
pressed  on  the  cell  surface  have  been  implicated  as 
possible receptors for hormones (2), toxins (12), viruses 
(24),  and  various growth  factors (19,  20).  It has  also  been 
suggested that  gangliosides serve  as  functionally important 
molecules in cell-substratum  interactions.  The recent devel- 
opment  of specific  monoclonal antibodies  directed  against 
the carbohydrate moieties of gangliosides (3,  8,  20,  27,  31, 
51)  will  aid  in  dissecting  the  biological  functions  of these 
membrane-embedded surface-exposed molecules. In this re- 
gard,  we recently described  monoclonal antibodies  (Mabs) ~ 
directed against the disialogangliosides GD3 and GD2 (8). 2 
~Abbrevialions  used in  this paper.  ELISA, enzyme-linked immunosorbent 
assay; FACS, fluorescence-activated  cell sorting; GRGDSPC, glycyl-L-arginyl- 
glycyl-L-aspartyl-L-seryl-L-prolyl-L-Cysteine;  Mabs, monoclonal  antibodies. 
2  Gangliosides  are termed according  to the nomenclature  of  Svennerholm (43). 
The epitopes recognized by these Mabs are known to involve 
the  terminal  sialic  acid  moiety since  either  neuraminidase 
treatment  or  mild  periodate  oxidation  abolishes  antibody 
reactivity (9).  Using these Mabs we could localize both GD2 
and GD3 in adhesion plaques and on the surface of human 
melanoma ceils. Moreover, biochemical analysis of such sub- 
strate-attached  adhesion  plaques,  left  behind  after  EDTA 
treatment  of metabolically labeled  human  melanoma cells, 
demonstrated that both GD2 and GD3 were indeed heavily 
concentrated at the interface of these cells and their substra- 
tum,  suggesting  that  these  molecules  may  play  a  role  in 
melanoma cell attachment (8). 
Initial evidence indicating ganglioside involvement in cell 
attachment came from a number of studies that demonstrated 
that the exogenous addition of gangliosides to cells in culture 
inhibited their attachment to the extracellular matrix protein 
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or more sialic acids were more inhibitory than monosialogan- 
gliosides, and it was suggested that the sialic acid moiety was 
critically involved in this form of cell-substratum interaction. 
Recent reports by Yamada et al. (50) and Spiegel et al. (42) 
demonstrated that gangliosides added to cells embedded in 
their membrane and caused retention  of fibronectin in cell 
surface-associated fibrillar networks. In addition, Dippold et 
al. demonstrated that Mab R24 directed to GD3 on human 
cells caused them to round up from tissue culture plastic (11). 
The evidence presented  by us and  others suggesting that 
gangliosides may play a key role in cellular adhesion mecha- 
nism(s) served  as a  rationale  for the experiments presented 
here. The results of  these studies suggest that gangliosides may 
play a general, yet critical, role in cell-substratum interactions 
rather than acting as receptors for specific extracellular matrix 
adhesive proteins. 
Materials and Methods 
Mabs 
The various sources of Mabs used in these studies are listed with their isotype 
denoted  in parentheses. Mabs 126 (IgM), MB3.6 (IgG3), I 1C64 (IgG3), 9.2.27 
(IgG2a), KSl/4 (IgG2a), and KSl/9 (IgM) were produced  in our laboratory. 
Mab 3F8 (IgG3) was provided by Dr. N. K. Cheung (Case Western  Reserve 
School of Medicine, Cleveland, OH). Mab HNK-I (lgM) and W6/32 (lgG2a) 
were generous  gifts from Dr.  R.  Quarles (National  Institutes  of Health,  Be- 
thesda,  MD) and Dr.  P.  Parham (Stanford  University  School of Medicine, 
Stanford,  CA), respectively. Mab 390 (IgG3) was provided  by Dr.  R. Seeger 
(UCLA School of Medicine). Monoclonal antibodies were isolated from murine 
ascites  fluid  and  purified  by  using a  protein  A-Sepharose (Pharmacia  Fine 
Chemicals,  Piscataway, N  J) immunoadsorbent procedure  as described previ- 
ously (30). The antibodies directed to GD2 and GD3 used in this study were 
shown not to react with carbohydrate  determinants  on glyeoproteins. Specifi- 
cally, these  Mabs  did  not immunoprecipitate  a  protein  from metabolically 
labeled melanoma cells, nor did they react by Western immunoblot analysis 
(data not shown). Furthermore,  M21  human melanoma cells pretreated  with 
mild trypsin actually reacted better with these Mabs yet failed to react with a 
Mab directed to the protein antigen recognized by Mab 9.2.27 (data not shown). 
Adhesive Substrates 
Fibronectin  and vitronectin  were isolated from human serum as previously 
described  (16a). Laminin  and  collagen  IV were  purchased  from  Bethesda 
Research Laboratories. 
Ganglioside Standards 
GD3 was generously provided by Dr. S. I. Hakomori (Fred Hutchinson Cancer 
Research  Center,  Seattle,  WA). GD2 was a  gift from Dr.  R.  K.  Yu (Yale 
University,  New Haven,  CT).  GM1,  GDla, and GT1  were purchased  from 
Supelco, lnc. (Bellefonte, NY). 
Cell Lines 
The human M21  melanoma and UCLA-P3  lung adenocarcinoma  cell lines 
were  kindly  provided  by  Dr.  D.  L.  Morton  (UCLA).  The  983  B  human 
melanoma cell line  was  provided  by  Dr.  H.  Koprowski  (Wistar  Institute, 
Philadelphia,  PA), and the SK-NAS human neuroblastoma  cell line was the 
gift of Dr.  L.  Helson  (Sloan-Kettering  Memorial  Hospital,  NY). The 983  B 
cells were grown in Dulbecco's  Modified Eagle's medium supplemented  with 
10% fetal calf serum. The M21  and SK-NAS cells were propagated in RPMI 
1640 media, supplemented  with  10% fetal calf serum. All cells were grown in 
tissue culture flasks (Coming Medical and Scientific, Medfield, MA) at 37"C in 
7.5% CO2/92.5% air and were shown to be free of mycoplasma  by repeated 
testing during these studies. 
Adhesion Assay 
Cells were grown as monolayers in tissue culture flasks, labeled in leucine-free 
growth media,  supplemented  with [aH]leucine (50/~Ci/ml)  at 37"C for 48 h. 
The cells were detached with an EDTA-containing  buffer (11) as previously 
described. The cells were washed with growth medium containing  1% fetal calf 
serum and 10  ~ cells in a volume of 250 ~1 were incubated  for 1 h at 4"C with 
the appropriate  Mab at a concentration  of 5 vg/ml. Cells were pelleted, washed 
twice to remove excess antibody,  resuspended at 2 x  105 cells/ml  in growth 
medium containing  1% fetal calf serum, and seeded at 5 x  103 cells/50 ~1 into 
individual 96-well polystyrene microtiter  plates (Flow Laboratories,  McLean, 
VA) that had been coated with adhesive substrates as previously described (16a, 
36). All substrates were allowed to interact  with microtiter  wells overnight at 
room  temperature  in  phosphate-buffered  saline  (PBS) at  5  ug/ml.  Before 
addition of cells, wells were coated with PBS containing  1% BSA for 1 h. After 
plating, cells were allowed to adhere at 37"C in a humidified incubator contain- 
ing 7.5% CO2. At specified intervals, the plates were inverted to facilitate the 
removal of unbound cells, and all wells were washed with 150 ~tl PBS, pH 7.2. 
The remaining attached cells were removed by the addition of 100 td/well of a 
solution  of 0.5  mg/ml trypsin  containing  0.2  mg/ml EDTA  (Gibeo, Grand 
Island, NY), followed by a  15-rain incubation  at 37"C and the harvesting of 
the cells onto glass fiber filters (Whatman Chemical Separation  Inc., Clifton, 
NJ) using a mash harvestor (Valcor Engineering Corp., Springfield, N  J). This 
was followed by the rinsing of all wells through the mash harvestor with 150 ~l 
PBS, followed by a wash with 5% trichloroacetic  acid and finally methanol. 
The fiber filter disks were placed into vials containing  5 ml liquid scintillation 
cocktail (Liquiscint, National  Diagnostics, Somerville, N  J), and the counts per 
minute were determined  in a  Liquid  scintillation  counter (Tracor  Analytic, 
Inc., Elk Grove Village, IL). Wells were harvested containing  cells that  were 
not allowed to adhere  in order to establish the total  counts per minute to 
calculate  the  percentage  of the  total  bound  cell population.  The  labeling 
procedure described above routinely resulted in ~50 cpm/cell.  Random fields 
were  counted  visually,  and  the  results  were  correlated  directly  with  those 
obtained by using the harvesting procedure described above (data not shown). 
Fluorescence-activated Cell Sorting (FACS) Analysis 
Quantitation  of cell surface antigen expression was achieved by FACS analysis 
as previously described (49), using nonfixed  viable cells stained  at 4"C. The 
hybridoma  fusion partner,  i.e., mouse myeloma protein  P3x63, served as the 
negative control for primary antibody binding. An additional  negative control 
included monoclonal  antibody  KSI/4 produced in our laboratory and shown 
to react with a 40-kD glycoprntein on the surface of human lung adenocarci- 
noma cells. This antibody  does  not react with either  human melanoma or 
neurnblastoma  cells (48). 
Enzyme-linked Immunosorbent Assay (ELISA) 
The relative expression of  each antigen was also measured with an ELISA assay 
on dried cell targets as previously described (16). 
Periodate Oxidation 
Cells were treated with sodium meta periodate in serum-free growth media at 
concentrations  ranging from 0.5-4 mM for 30 min at 4"C in the dark. The 
cells were immediately washed twice with ice-cold growth medium and used in 
the adhesion assay or tested for antigen reactivity by ELISA. 
Results 
Monoclonal Anti-ganglioside Antibodies Inhibit Cell- 
Substrate Interactions 
To determine the relative effects of Mabs directed to ganglio- 
side  antigens on the cell attachment  process,  human mela- 
noma or neuroblastoma cells were allowed to attach to various 
adhesive  substrates,  immobilized  on  microtiter  wells  after 
being preincubated with one of several monoclonal antibod- 
ies. As shown in Fig.  1 and Table I, Mabs directed to either 
GD3 or GD2 inhibited attachment of human melanoma cells 
983 B to fibronectin, laminin, vitronectin, and collagen type 
IV, whereas  no such effect was observed when these  same 
cells were tested in the absence of Mab pretreatment or after 
preincubation with Mab 9.2.27 directed to a  250-kD mela- 
noma-associated chondroitin sulfate  core glycoprotein (16). 
In several experiments we observed essentially identical cell 
attachment  when  983B  human  melanoma  cells  were  pre- 
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binding antibody), or PBS; thus, any one of these reagents
could represent control binding.
As expected, an additive inhibition of cell attachment was
observed in each case when anti-GD2 and anti-GD3 were
used in combination . This finding suggests that both ganglio-
sidesare involved in the attachment process of these cells and
may interact independently, although possibly by a similar
mechanism . The M21 melanoma cells were also examined
Figure 1. The effects of monoclonal anti-ganglioside antibodies on
binding ofhumanmelanoma cells to various substrates. Metabolically
labeled983B human melanoma cells (5 x l0') were allowed to attach
to microtiter wells which hadbeen coated overnight with 5 jug/ml in
PBS of either fibronectin, laminin, vitronectin, or collagen IV, as
described in Materials and Methods . Before addition to coated wells,
the cells were allowed to react with either Mab 9.2.27 (anti-250-kD
chondroitin sulfate core glycoprotein, p), 1 IC64 (anti-GD3, E), 3178
(anti GD2, ®), or the combination of Mabs I IC64 and 3178 (03) for I
h at 4°C and washed free of excess antibody . The data are expressed
as the percentage ofthe total cell population attached after 30 min at
37°C . Each bar represents the mean± SD offive replicates . In control
wells not treated with substratewe never observed more than 5% of
the cells attached over the course of the assay .
Table 1. Reactivity ofMabs and Their Effect on Adhesion ofHumanMelanoma and Neuroblastoma
Cells to Various Substrates*
for their ability to attach specifically to the heptapeptide
glycyl-L-arginyl-glycyl-L-aspartyl-L-seryl-L-prolyl-L-cysteine
(GRGDSPC, which represents the cell attachment site ofthe
fibronectin molecule (32, 33, 16a, 36). As shown in Fig . 2
both monoclonal anti-ganglioside antibodies inhibit this in-
teraction . In control experiments in which these cells were
treatedwith anti-HLA or no antibody at all, 54% of the cells
were bound in 30 min . Prior treatment with either anti-GD2
or anti-GD3 reduced this by -50% . The control peptide
GRGDSPC (33), which was synthesized by substituting a
glutamic acid (E) for an aspartic acid residue (D), did not
mediate significant cell attachment, never promoting more
than 5% cell attachment (data not shown) . As with the other
substrates tested, Mabs directed to GD2 andGD3,when used
together, produced an additive inhibition of cell attachment
ofM21 cells (data not shown).
0 m
N
U
Figure 2 . Monoclonal anti-ganglioside antibodies inhibit binding of
human melanoma cells to the synthetic peptide GRGDSPC . Meta-
bolically labeled M21 human melanoma cells (5 x 10 3 ) were allowed
to attach to microtiter wells which had been precoated with the
synthetic peptide GRGDSPC as described (33) . Before addition to
coated wells, the cells were allowed to react with Mabs W6/32 (anti-
HLA), MB3.6 (anti-GD3), or 126 (anti-GD2) for 1 h at 4°C and
washed free of excess antibody . The data are expressed as the per-
centage of the total cell population attached after 30 min at 37°C .
Each bar represents the mean ± SD of five replicates.
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"Adhesion of cells to various immobilized extracellular matrix proteins was performed as described in Materials and Methods .
FACs analysis was performed on nonfixed viable cells using indirect immunofluorescence as described in Materials and Methods . The antigenic expressions was
quantitated in terms of mean intensity of fluorescence and percentage of cells in the population demonstrating positive staining above background, which was
determined using P3x63 mousemyeloma protein as nonbinding control .
A+ indicates the ability of each Mab to reduce cell attachment to various substrates by at least 2 SD ofthe mean control binding as described in Materials and
Methods.
MAb (isotype) Antigen
M21
MIF %+
FACs analysis=
983B
MIF
SK-NAS
MIF %+
ELISA
M21
reactivity
983B
(OD492)
SK-NAS
Inhibition of
stratum interaction°
M21 983B
cell-sub-
SK-NAS
MB3.6 (IgG 3) Carbohydrate on GD3 (8) 69 64 65 88 0 0 0.929 0.492 0.039 + + -
11C64 (IgG 3) Carbohydrate on GD3 (8) 75 70 68 86 0 0 0.585 0.631 0.025 + + -
126 (IgM) Carbohydrate on GD2 (8) 186 100 137 99 118 86 1 .112 0.664 1 .61 + + +
3178 (19G3) Carbohydrate on GD2 (39) 127 100 110 86 87 75 1 .933 NT 0.688 + + +
9.2.27 (IgG2a) Chondroitin sulfate proteo- 137 99 61 89 0 0 1 .150 0.816 0 - - -
glycan (16)
KS 1/9 (IgM) Carbohydrate neutral glyco- 42 5 39 4 0 0 0.209 NT 0
lipid (48)
W6/32 (IgG2a) Histocompatability class I 56 99 92 96 60 81 1 .616 0.625 0.943
protein (29)
390 (IgG2a) 26-kD Thy-1 protein (41) 0 0 0 0 50 86 0 0 0.608
KSI/4 (IgG2a) Adenocarcinoma-associated 0 0 0 0 0 0 0 0 0
40-kD glycoprotein (48)
P3X62 (IgG,) None 0 0 0 0 0 0 0 0 0M21  and 983B human melanoma cells were also tested for 
their ability to attach to tissue culture plastic. In this case, we 
observed little or no  inhibition with  anti-ganglioside Mabs 
within the first 30 min of cell attachment (data not shown). 
However, optimal binding of these cells requires -2 h at 37"C, 
when  cell-derived and  serum-derived cell adhesive proteins 
would probably play a role. 
To examine the kinetics of inhibition of cell attachment by 
anti-ganglioside Mabs, M21  melanoma cells were allowed to 
attach to either fibronectin (Fig. 3,  top) or laminin (Fig. 3, 
bottom) for various times after being pretreated with either 
anti-GD3, anti-GD2,  or control  Mab,  i.e., anti-HLA (W6/ 
32).  It  is  apparent  that  both  monoclonal  anti-ganglioside 
antibodies significantly inhibit the attachment of these cells 
to both substrates. Furthermore, this inhibition of cell attach- 
ment  obtained with  each antibody is detectable within the 
first 5  rain of binding time, suggesting that GD2 and GD3 
may be involved in the initial events of M21  cell attachment. 
Specifically, anti-GD3  inhibited M21  cell binding to  both 
substrates by ~50%  whereas anti-GD2 inhibited 90%  of cell 
binding to fibronectin and 60%  to laminin after 15 min. To 
determine  whether  ganglioside involvement  in  cell  attach- 
ment  was  restricted to  human  melanoma  cells,  a  human 
neuroblastoma cell line (SK-NAS) was investigated that ex- 
pressed high levels of GD2 but contained no detectable GD3. 
As shown in Table II, Mab 126 directed to GD2 significantly 
inhibited  these  cells'  capacity  to  attach  to  fibronectin  or 
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Figure 3.  Effects of monoclonal antiganglioside antibodies on the 
kinetics of M21 human melanoma cells attachment to fibronectin or 
laminin. Metabolically  labeled M21 human melanoma cells (5 x  103) 
were allowed to attach for various times to microtiter wells coated 
with either fibronectin or laminin. Before addition to substrate-coated 
wells, the cells were allowed to react with Mabs W6/32 (anti-HLA, 
i--I), 1  IC64 (anti-GD3,/x), or 3F8 (anti-GD2, ©) for 1 h at 4"C and 
washed  free of excess antibody. The data are expressed  as the total 
number of cells (counts per minute bound) at the designated times. 
Each point represents the mean ___ SD of five replicates. 
Table H. Effects of  Anti-GD2 Mab on the Attachment of  SK- 
NAS Human Neuroblastoma Cells to Fibronectin and 
Laminin 
Cell binding* (% of control) 
Mab  Fibronectin  Laminin 
KS1/4  100  100 
390  88  -- 
W6/32  97  100 
126  47  52 
* SK-NAS cells were preincubated with various Mabs and allowed to attach to 
substrate-coated microtiter wells  for  10  rain  as described  in  Materials and 
Methods. Cell attachment is expressed as the percentage of control in which 
cells were preincubated with Mab SKI/4, which does not bind to these cells, 
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Figure 4. Effects of anti-GD2 Mab on the kinetics of SK-NAS human 
neuroblastoma cell attachment to fibronectin.  Metabolically labeled 
SK-NAS human  neuroblastoma cells  were  allowed  to  attach  for 
various times to microtiter wells which had been coated with fibro- 
nectin.  Before addition to substrate-coated wells, the cells were al- 
lowed to react with Mabs KS1/4 (nonbinding control, O), W6/32 
(anti-HLA, II), 390 (anti-Thyl, 0), or 126 (anti-GD2, I-I) for 1 h at 
4"C and washed  free of excess antibody. The data are expressed as 
the percent of cells attached at each designated  time. Each point 
represents the mean + SD of five replicates. 
laminin as compared with two other antibodies that bind to 
the neuroblastoma cell surface (Mabs 390 and W6/32) or to 
a Mab that does not bind to these cells (Mab KSI/4). More- 
over, Mab 3F8 (IgG3) also directed to GD2 showed a similar 
capacity to  inhibit SK-NAS cell attachment  to  fibronectin 
or  laminin  (data  not  shown).  As  expected,  the  anti-GD3 
antibodies had no effect on the attachment of this cell line 
(Table I) since neuroblastoma cells do not express GD3.  In 
two  independent  experiments,  Mab  MB3.6  was  shown  to 
inhibit <5-10%  of SK-NAS cell attachment,  which  readily 
compares with either binding or nonbinding control antibod- 
ies  as  documented  in  Table  II.  A  kinetic  analysis  of the 
inhibition induced by anti-GD2 antibody indicated that the 
binding  of SK-NAS  cells to  either  fibronectin  (Fig.  4)  or 
laminin (data not shown) can also be inhibited by 40-50% 
within  l0  min  of cell attachment.  These data suggest that 
GD2 expressed on neuroblastoma cells probably plays a sim- 
ilar role in cell-substratum interactions, as do both GD3 and 
GD2 that are expressed on the melanoma cells examined in 
this study. At later times (30-40 min) of cell attachment, the 
inhibition of neuroblastoma cell attachment decreased some- 
what, ranging from 20 to 30%. 
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Cells Preattached  to Immobilized Fibronectin  Causes 
Cell Rounding and Detachment 
To determine whether cells preattached to fibronectin could 
be displaced by monoclonal anti-GD3 antibody, M21  mela- 
noma cells were allowed to bind to fibronectin for 1 h, after 
which they were overlaid with either growth medium alone, 
or  with  growth  medium  containing  purified  Mabs  MB3.6 
(anti-GD3) or 9.2.27  (anti-250-kD glycoprotein). As shown 
in  Fig.  5,  the  addition  of MB3.6  to  these  cells  caused  a 
significant  cell  rounding  and  detachment  within  4  h.  The 
observed  effect  increased  proportionally  with  increasing 
amounts  of antibody  added,  with  maximum effects being 
observed when melanoma cells were incubated with 0.5-1.0 
mg/ml antibody. Cell viability is not affected by this treat- 
ment, since trypan blue exclusion demonstrated >95%  via- 
bility among the MB3.6-treated cells even after 24 h. Identical 
concentrations of Mab 9.2.27  used as a control produced no 
effect on either cell morphology or adherence to fibronectin 
at any concentration tested (Fig.  5,  B  and  C).  In a  similar 
experiment Mab 126 (anti-GD2), which reacts with 100% of 
the M21  cells, could cause >95% cell rounding, whereas, as 
expected, Mab W6/32 (anti-HLA) had virtually no effect (data 
not shown). 
Relative Expression of Ganglioside Antigens on the 
Surface of  Human Melanoma and 
Neuroblastoma  Cells 
The relative surface expression of various antigens defined by 
the  Mabs used  in  this  study  is  presented  in  Table I.  It is 
apparent that the two anti-GD3  Mabs,  MB3.6  and  11C64, 
that inhibit  melanoma cell attachment, bind to both mela- 
noma cell lines in an equivalent manner to that  seen with 
Mabs  W6/32  and  9.2.27  that  have  no  effect  on  the  cell 
attachment process. This can be observed by either ELISA 
reactivity on  whole  cells or by applying FACS  analysis to 
determine the  relative antigen  density by measuring mean 
intensity of fluorescence and the  percentage of cells  in  the 
population  that  express the  antigen.  The  specificity of the 
anti-GD3 and GD2 antibodies to inhibit melanoma or neu- 
roblastoma cell attachment to extracellular matrix proteins is 
further underlined by the observation that a variety of Mabs 
directed to either protein or carbohydrate determinants on a 
number of other cell  surface  molecules did  not  cause any 
significant inhibition of cell attachment (Table I). In addition, 
similar results were obtained with both anti-GD2 Mabs,  126 
(IgM) and 3F8 (IgG3), demonstrating that the inhibition of 
cell attachment observed is independent of antibody isotype. 
Further  evidence  for the  specificity of this  reaction  comes 
Figure 5. Effects of anti-GD3 Mab on M21  human melanoma cells preattached to a fibronectin substrate. M21 cells were allowed to attach to 
fibronectin (5 ug/ml)-coated plastic for l h at 37"C. These attached cells were then overlaid either with growth media alone (A), growth media 
containing purified Mab 9.2.27  (anti-250-kD chondroitin sulfate proteoglycan core protein) at either 0.5 or 1.0 mg/ml (B and C), or purified 
Mab  MB3.6  (anti-GD3) at 0.1,  0.5,  or  1.0  mg/ml (D-F,  respectively). After incubation was carried out at  37"C  for 4  h,  the cells  were 
photographed using a Leitz inverted microscope at 23x. Bar,  100 um. 
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that expresses GD2 but not GD3 can only be inhibited in its 
ability to attach to various substrates by anti-GD2 Mabs. This 
cell line, similar to the melanoma cell lines studied, expresses 
other cell surface antigens that apparently have no involve- 
ment in the cell attachment process. 
Periodate Oxidation of Cell Surface Gangliosides 
Inhibits Attachment of Human Melanoma and 
Neuroblastoma Cells to Fibronectin and Laminin 
To assess the  structural  components of GD2 and  GD3 in- 
volved in cell attachment, human melanoma cells 983B and 
M21, SK-NAS neuroblastoma, or UCLA-P3 lung adenocar- 
cinoma cell lines were treated with growth medium containing 
from 0.5 to 4 mM sodium-meta-periodate. This reaction on 
ice  and  in  the  dark  for 30  min  preferentially  oxidizes  the 
exocyclic arm of  terminal, unsubstituted sialic acids (47). Cells 
treated  in  this  manner were then  tested  for their  ability to 
adhere to a fibronectin and/or laminin substrate to determine 
whether  surface  exposed  terminal  sialic  acid  residues  are 
involved in their cell attachment processes. As shown in Table 
III, all cell lines treated in this manner show a dose-dependent 
decrease in cell attachment. These same conditions of perio- 
date  oxidation also destroyed the epitope  on the  GD3 and 
GD2 antigens recognized by Mab I 1  C64 and 126, respectively 
(Fig.  6).  In contrast,  Mabs  9.2.27  and  W6/32,  which react 
with protein epitopes on these same cells,  were unaffected at 
all concentrations of periodate used. In this regard, we have 
previously shown that periodate oxidation of melanoma gan- 
gliosides  under  these  same  conditions  results  in  a  specific 
attack on the exocyclic arm of sialic acid, causing a  loss of 
binding of Mabs directed to either GD3 or GD2 (l 9).  How- 
ever, treatment of cells with periodate in this manner affected 
neither cell viability, as measured by trypan blue exclusion, 
nor protein synthesis, as determined by [3H]leucine incorpo- 
ration into total cell protein after 24 h  of labeling (data not 
shown). These data suggest that the cells are not compromised 
metabolically by this type of mild periodate oxidation of the 
cell surface. 
The UCLA-P3 lung adenocarcinoma cell line was used as 
a control since it expresses GM3 as its major ganglioside yet 
contains neither GD2 nor GD3 (data not shown). As shown 
in Table III, periodate oxidation inhibits UCLA-P3 cells from 
binding to fibronectin,  suggesting that in this  case,  the cell 
attachment process may involve oligosaccharides other than 
GD2 or GD3. 
Table IlL Effect of  Periodate on Cell Attachment* 
M21  938B  SK-NAS  UCLA-P3 
Fibronec-  Fibronec-  Fibronec-  Fibronec- 
Periodate  tin  Laminin  tin  Laminin  tin  tin 
mM 
0  77---3'  35_+5  84__+8  27_3  67___3  15---3 
0.5  71___4  23___2  74+4  25__+2  80___3  11+3 
1.0  68-+4  18___1  72__+7  24_2  62___2  9---3 
2.0  62---2  13_1  62_4  20_3  58+2  5-.+2 
4.0  49___1  12+3  57+6  12___3  26+1  4+1 
* Adhesion of periodate treated cells to immobilized fibronectin or laminin was 
performed as described in Materials and Methods. 
Percentage of cells attached  in 15 min (mean -+ SE of four replicates). 
2.0 
1.5 
1.0 
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0.4 
0.2 
0 
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Periodate (mM) 
Figure 6. Periodate oxidation on cells of  M21 human melanoma cells 
depletes their expression of  GD2 and GD3 gangliosides. M21 Human 
melanoma cells were treated with growth media containing  0.5--4.0 
mM sodium-meta-periodate  on ice and in the dark for 30 min. After 
they were washed, the cells were dried onto microtiter wells for antigen 
detection  by ELISA as described in Materials and Methods.  Mabs 
9.2.27 (anti-250-kD  chondroitin  sulfate core glycoprotein), W6/32 
(anti-HLA),  1  IC64 (anti-GD3),  and  126 (anti-GD2)  were used as 
primary antibodies.  Each point represents the mean _+ SE of four 
replicates. 
Discussion 
Specific Mabs directed to well-defined epitopes expressed on 
the  surface  of human  melanoma  and  neuroblastoma  cells 
were used as molecular probes to provide evidence that the 
carbohydrate  moieties  of the  disialogangliosides  GD3  and 
GD2 are involved in the attachment of these cells to a variety 
of substrate  adhesive  proteins.  Furthermore,  these  studies 
demonstrate that Mabs directed to either GD2 or GD3 also 
inhibit melanoma cell attachment to the GRGDSPC peptide 
that is known to specify the cell attachment site of fibronectin 
(33). Moreover, after separating GD3 and GD2 on thin-layer 
chromatography plates,  we  could  not  observe  any  specific 
interaction with  ~2SI-labeled fibronectin or a  120-kD cell at- 
tachment  domain-containing  fragment  (34)  with  either  of 
these gangliosides; however Mabs directed to GD2 and GD3 
reacted  specifically with  their  respective  antigens  on  these 
chromatograms (data not shown). It is also important to note 
that none of the Mabs directed to either GD2 or GD3 could 
induce 100% inhibition of cell attachment. This observation 
is consistent with the concept that gangliosides expressed on 
these  cells  do not independently promote cell binding and 
thus  fail to  act as specific receptors  for a  substrate.  Taken 
together,  these  observations  suggest  that  the  role  of these 
gangliosides in the cell attachment process of human mela- 
noma cells may involve secondary events on the surface that 
result in the promotion  of optimal cell-substratum  interac- 
tions. 
A  kinetic  analysis  of the  inhibition  of neuroectoderm- 
derived tumor cell attachment to extracellular matrix protein 
by anti-GD2 and GD3 antibodies suggests that these disialo- 
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this process since a significant inhibition of cell attachment 
was observed in the presence of these antibodies within the 
first 5-10 min of binding time. Mabs directed to gangliosides 
on these tumor cells failed to induce a significant redistribu- 
tion of this antigen at 37"C up to 30 min, suggesting that the 
observed effects were not due to antibody-mediating capping 
on the surface of these cells (Cheresh, D. A., and J. Claypool, 
unpublished observations). However, one cannot rule out that 
gangliosides may play a role in cell attachment at later times 
as well since inhibition was still observed after 30 min. In this 
regard, it is not inconceivable that anti-ganglioside Mabs in 
some way induce an as yet undefined membrane perturbation 
resulting in an altered cell metabolism and reduced cell at- 
tachment. This hypothesis is supported by other reports in- 
dicating that anti-ganglioside antibodies can alter cell growth 
and metabolism that may explain in part how these antibodies 
inhibit  cell  attachment (21,  22).  However, this  contention 
does not explain our results since we observed no decrease in 
cell viability when M21  melanoma cells were allowed to bind 
as  much  as  1 mg/ml  of purified  Mab  MB3.6  (anti-GD3) 
during a period of 24 h. Indeed, if the anti-ganglioside Mabs 
could perturb the cell membrane one would expect an in- 
creased inhibitory effect on cell attachment with binding time; 
however, this is not the case. The fact that Mabs of various 
isotypes directed  to a  number of other antigen epitopes on 
melanoma and neuroblastoma cells fail to inhibit cell attach- 
ment suggests that disialogangliosides GD2 and GD3 indeed 
play  a  role  in  the  attachment  processes  of these  cells  to 
extracellular matrix proteins. This contention is strengthened 
and  extended  by the  finding  that  the  addition  of purifed 
MB3.6 (anti-GD3) to M21 melanoma cells that were allowed 
to preattach to immobilized fibronectin caused significant cell 
rounding and detachment from the substrate. In fact, after 4 
h  of antibody exposure most (~62%) of the cell population 
had lost its spread appearance. Since FACS analysis demon- 
strated that Mab MB3.6 reacted with 64% of the M21  mela- 
noma ceils, one would not expect inhibition of attachment to 
exceed this percentage.  This effect was dependent on both 
antibody concentration  and time and could  not simply be 
attributed  to  loss of cell  viability, which  was  found  to be 
>95% by trypan blue exclusion. As expected, Mab  126 that 
reacts with 100% of the M21 cell population by FACS analysis 
(Table I) caused cell detachment and rounding of >95% of 
the cell in the population. In a control experiment, purified 
Mab 9.2.27  or W6/32  at identical concentrations  failed to 
change cell  morphology or cell attachment,  suggesting that 
mere binding of an antibody to an epitope that is expressed 
on the melanoma cell  surface is insufficient to mediate this 
effect. 
We previously reported the presence of GD2 and GD3 in 
focal adhesion plaques of M21 cells and suggested that these 
molecules are involved in the attachment of such cells at the 
cell-substrate interphase (8). Reports by others also indicated 
that cell surface-associated gangliosides are involved in cell 
adhesions processes (3,  20,  27,  31,  51).  Thus, Perkins et al. 
demonstrated that exogenously added gangliosides could in- 
hibit  cell  binding  to  fibronectin  (31).  These  investigators 
proposed that the binding affinity of fibronectin immobilized 
in the extracellular matrix may be increased by gangliosides 
at the cell surface by some form of cooperative interaction. 
Their results also support the findings of Rauvala et al. (38) 
that indicate that exogenously added gangliosides could in- 
hibit  cell  attachment to  immobilized lectin.  Both  of these 
findings are consistent with our results and strongly implicate 
gangliosides as playing a general role in cell attachment. 
Kleinman et al. (20) and Yamada et at. (51) demonstrated 
that di- and trisialogangliosides added to the culture medium 
effectively inhibit  cell  binding to fibronectin.  Furthermore, 
Kleinman et al. showed that prior treatment of these ganglio- 
sides  with  periodate eliminated  their  ability to  inhibit  cell 
attachment (20).  These observations are in accord with our 
results,  which clearly demonstrate their similar conditions of 
periodate  oxidation  could  not  only  destroy  the  antigenic 
epitope on the cell surface recognized by the anti-ganglioside 
Mabs but also cause a significant reduction in cell attachment, 
indicating that the antibody binding site on these gangliosides 
involves a defined structure that can be specifically oxidized 
by periodate. This contention is strengthened further by our 
previous observation that whenever GD3 contains a relatively 
rare 9-O-acetyl ester on the exocyclic arm of its terminal sialic 
acid residue, periodate oxidation is prevented, thus protecting 
this antigen epitope against periodate-induced oxidation (9). 
These data suggest that an intact, unsubstituted terminal sialic 
acid  residue  is  critical  for ganglioside  involvement in  cell 
attachment.  The  fact  that  attachment  of UCLA-P3  cells, 
which  do  not  contain  GD2  or GD3,  can  be  inhibited  by 
periodate oxidation suggests that sialic acid present on other 
gangliosides may be involved, i.e.,  possibly GM3 which rep- 
resents the major ganglioside expressed by these cells (data 
not shown). The role of sialic acid in melanoma and neuro- 
blastoma cell attachment was further established using neur- 
aminidase. Thus, pretreatment of 983B and M21  melanoma 
cells or SK-NAS neuroblastoma cells with Clostridium per- 
fringens neuraminidase (Sigma Chemical Co., St. Louis, MO) 
at 100 mU/ml for 1 h at 37"C resulted in >80% loss of GD2 
and GD3 antigen expression and an ~40% reduction in cell 
attachment to immobilized fibronectin (Cheresh, D. A., and 
K. Mujoo, unpublished data). Removal of sialic acid in this 
manner did not decrease cell viability or protein synthesis and 
failed to alter the protein antigens recognized by Mab 9.2.27 
or W6/32. 
One possible functional role suggested for the terminal sialic 
acid moiety on di- and trisialogangliosides has been that of 
Ca  ++ binding (1,  14), an event known to require not only the 
carboxyl group on the  1 position of sialic  acid but also an 
intact exocyclic arm (7, 8, and 9 positions) (18). In fact, recent 
studies have demonstrated that complexes between polysialo- 
gangliosides and Ca  ++ induce a specific protein phosphoryla- 
tion  pattern  within  a  membrane fraction isolated from rat 
brain (14).  A  possible involvement of Ca  ++ with GD2 and 
GD3 is suggested by our preliminary observations that 4~Ca++ 
interacts with either of these two purified gangliosides im- 
mobilized on microtiter wells. The specificity of this interac- 
tion was indicated by competition with excess cold Ca  ++  . 
In view of recent reports indicating the presence of specific 
cell surface glycoprotein receptors for fibronectin (5,  13, 36) 
and laminin (37), it is important to determine whether gan- 
gliosides that are somehow involved in cell adhesion processes 
are either dependent or independent of a protein receptor(s). 
Recent reports that demonstrated the presence of a trypsin- 
resistant  glycoprotein receptor  for fibronectin  (13,  45,  46) 
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age  in  the  presence of Ca  ++  since  chelation  of this  cation 
sensitized it to trypsin degradation, causing subsequent loss 
of cell attachment (7, 28). Thus, it is possible that the electro- 
static  environment created  by  a  ganglioside-Ca  ++  complex 
may indeed  stabilize the interaction of a  given cell surface 
glycoprotein receptor with a given adhesive protein substrate. 
This hypothesis is strengthened by a number of reports indi- 
cating that gangliosides can cooperatively interact with gly- 
coprotein receptors at the cell surface (2, 4). In this regard, it 
has  been  shown  that  the  receptor  for  thyroid-stimulating 
hormone  may  involve  a  glycoprotein/ganglioside  complex 
(2). Also, in a recent report, Okada et al. demonstrated a close 
functional  association  between  gangliotriaosylceramide 
(GM3)  and  the transferrin  receptor on  murine lymphoma 
cells which, in turn, may regulate the internalization of trans- 
ferrin (26). Thus, depending on its particular oligosaccharide 
moiety, a ganglioside may serve to induce a preferred orien- 
tation  or  create  an  electrostatic  environment  suitable  for 
optimal receptor-ligand interaction on the cell surface. 
The fact that GD2 and GD3  represent the major ganglio- 
sides on the surface of both human melanoma and neuro- 
blastoma cells and apparently play a role in their attachment 
to extracellular matrix proteins suggests that structurally sim- 
ilar gangliosides on other cell types may have similar func- 
tional capacities.  In fact,  it was recently demonstrated that 
GM3,  a  major ganglioside  on the surface of baby  hamster 
kidney  cells,  could  be  localized  in  the  detergent-insoluble 
substrate attachment matrix of these cells. Furthermore, when 
GM3 was added to the culture media of  these cells, attachment 
and spreading were inhibited (27). 
The model system described in the present report was used 
for two reasons; first, we had well characterized Mabs directed 
to GD2 and GD3,  and second, these are the major ganglio- 
sides  associated  with  these  particular cell  types.  Whenever 
additional  Mabs become  available,  it  will  be  important to 
determine  whether gangliosides  on  other cell  types  play  a 
similar role in cell-substrate attachment as that described for 
GD3  and  GD2  on  human  melanoma and  neuroblastoma 
cells to ascertain whether this is a common biological event. 
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